Compare Dell Technologies Inc (DELL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Twist Bioscience Corp — how do they compare? Dell Technologies Inc trades at $447.65 (market cap $295.86B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Dell Technologies Inc is far larger — about 37.8× Twist Bioscience Corp's market cap, and Dell Technologies Inc pays a 0.55% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DELL | TWST | |
|---|---|---|
Market Cap | $295.86B | $7.82B |
Sector | Technology | Health |
52-Week High | $467.27 | $124.88 |
52-Week Low | $111.10 | $24.16 |
Enterprise Value | $315.44B | $7.75B |
Dividend Yield | 0.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $453.78, up 3.69% in the last 24 hours, reflecting strong momentum driven by AI server demand and consistent earnings beats. The technical outlook is bullish with support at $428 and resistance at $467. Recent quarterly EPS results exceeded expectations, with Q1 2026 actual EPS of $4.86 beating the $2.96 estimate, signaling robust operational performance. Revenue for 2025 reached $95.57 billion, with a net income margin of 6.28%, while analyst consensus leans bullish with a $503.76 price target.
The outlook for Dell is positive, supported by growth in AI infrastructure and a solid financial trajectory, but risks include competitive pressures and reliance on tech spending cycles. Investment opportunities center on expanding profit margins and market share in servers, though investors should monitor debt levels and macroeconomic factors that could impact stock volatility.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
